A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisN. Shah, Patrycja Olszynski, L. Sokol, S. Verstovsek +8 more200868 citationsSemantic ScholarSave
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitorS. Verstovsek, C. Tam, M. Wadleigh, L. Sokol +8 more2013Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis42 citations Open accessSemantic ScholarSave
Quadratus lumborum catheters for breast reconstruction requiring transverse rectus abdominis myocutaneous flapsNicole Z. Spence, Patrycja Olszynski, A. Lehan, J. Horn +1 more2016Journal of Anesthesia26 citationsSemantic ScholarSave
